{"public_id":"co_a402d4faa347171d972d8daa436ab8e2","status":"active","merged_into_public_id":null,"resolved_public_id":"co_a402d4faa347171d972d8daa436ab8e2","name":"Kelussia powder","description":"Powdered Kelussia odoratissima administered orally in the human comparison described in the abstract.","aliases":["2 g/day Kelussia powder"],"types":["supplement"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":30901307,"title":"Kelussia odoratissima Mozaffarian and dyslipidemia","citation_count":4,"url":"https://sah.borca.ai/papers/30901307"}],"claims":[{"public_id":"cl_737d4868fe5c28cc67d78c6cc79677d4","text":"In hyperlipidemic patients, 2 g/day Kelussia powder plus 40 mg/day lovastatin did not produce significant changes in fasting blood glucose or lipid profile compared with lovastatin alone over 14 and 30 days.","corpus_id":30901307,"url":"https://sah.borca.ai/claims/cl_737d4868fe5c28cc67d78c6cc79677d4"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_a402d4faa347171d972d8daa436ab8e2","url":"https://sah.borca.ai/concepts/co_a402d4faa347171d972d8daa436ab8e2"}